Author:
Rostaing Lionel,Bunnapradist Suphamai,Grinyó Josep M.,Ciechanowski Kazimierz,Denny Jason E.,Silva Helio Tedesco,Budde Klemens,Denny Jason E.,Kulkarni Sanjay,Hricik Donald,Bresnahan Barbara A.,Bunnapradist Suphamai,El-Sabrout Rafik A.,Chan Laurence K.,Ciancio Gaetano,El-Ghoroury Mohamed A.,Goldstein Michael J.,Gaston Robert S.,Gohh Reginald Y.,Killackey Mary T.,King Anne,Knight Richard J.,Kore Arputharaj H.,Sudan Debra L.,Chapochnick Friedmann Javier,Mulgaonkar Shamkant P.,Nolan Charles,Pankewycz Oleh G.,Pirsch John D.,Schaefer Heidi M.,Steinberg Steven M.,Gelb Bruce E.,True Karin A.,West-Thielke Patricia M.,Waybill Mary M.,Wolf Joshua H.,Ketel Beverley L.,Harland Robert C.,Shihab Fuad S.,Cassuto Elisabeth,Le Meur Yannick,Rostaing Lionel,Mariat Christophe,Grinyó Josep Maria,Puig Jose,Seron Daniel,Tisone Giuseppe,Ciechanowski Kazimierz,Foroncewicz Bartosz,Wlodarczyk Zbigniew,Budde Klemens,Witzke Oliver,Mondragon Guillermo A.,Mancilla Urrea Eduardo,Alberu Gomez Josefina,Reyes Acevedo Rafael,Rial Maria del Carmen,Novoa Pablo A.,Silva Helio T.,Garcia Valter D.,Carvalho Deise D.,Santamaria Saber Luciana T.,Contieri Fabiana L.,Bastos Marcos G.,Manfro Roberto C.,Kanellis John,Eris Josette,O’Connell Philip,Hughes Peter,Russ Graeme,Pidgeon Grant B.,Dittmer Ian D.,Kee Terence,Vathsala Anantharaman,Naumovic Radomir,Mitic Igor,Parmjeet Randhawa
Reference50 articles.
1. OPTN/SRTR 2012 Annual Data Report,2014
2. US Food and Drug Administration. Draft Guidance on Tacrolimus. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm181006.pdf. Accessed July 2, 2014.
3. Prograf [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; September 2013.
4. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers;Zaltzman;Transpl Int,2014
5. Neurotoxicity of calcineurin inhibitors: impact and clinical management;Bechstein;Transpl Int,2000